Genetics Group 4 Video Quiz
From:christina solvinViews:1 0ratingsTime:02:59More inPeople Blogs

Follow this link:
Genetics Group 4 Video Quiz - Video

Recommendation and review posted by Bethany Smith

UNL ASCI100 BQ
Animal Science 100 class on "Befuddling Questions" about agriculture. Covers how good quality steaks are produced from genetics, nutrition, handling, and processing and is made for younger children. Sources include: Dr. Berger, Dr. Nielsen, Dr. Schmitt, and Dr. Calkins from University of Nebraska-Lincoln.From:Ashley McCoyViews:2 0ratingsTime:05:35More inPeople Blogs

See the rest here:
UNL ASCI100 BQ - Video

Recommendation and review posted by Bethany Smith

Knockout Mouse - Wiki Article
A knockout mouse is a genetically engineered mouse in which researchers have inactivated, or "knocked out," an existing gene by replacing it or disrupting it with an artificial piece of DNA. The loss... Knockout Mouse - Wiki Article - wikiplays.org Original @ http All Information Derived from Wikipedia using Creative Commons License: en.wikipedia.org Author: Maggie Bartlett, NHGRI. Image URL: en.wikipedia.org ( This work is in the Public Domain. ) Author: Maggie Bartlett, NHGRI. Image URL: en.wikipedia.org ( This work is in the Public Domain. ) Author: Lexicon Genetics Incorporated Image URL: en.wikipedia.org ( This work is in the Public Domain. ) Author: Kjaergaard Image URL: en.wikipedia.org ( Creative Commons ASA 3.0 )From:WikiPlaysViews:0 0ratingsTime:10:45More inEducation

See the rest here:
Knockout Mouse - Wiki Article - Video

Recommendation and review posted by Bethany Smith

Ceremony for the 100000th rice-breeding cross, a major milestone in IRRI #39;s 52-year history
Also see: youtu.be On 29 November 2012, the IRRI community celebrated the 100000th rice breeding cross at IRRI, a true milestone in the Institute #39;s 52-year history existence. The parents for the 100000th cross were IR09M105 and NSICRC 214.The objective of this particular cross was to improve eating quality. Making opening comments at the event were Eero Nissila, head of Plant Breeding, Genetics and Biotechnology at IRRI -www.irri.org - and Glenn Gregorio, senior scientist/plant breeder - http://www.irri.org Special guest at the event was Rizal M. Herrera (see 1:38 and 8:13 into video), who was among the first breeders to make crosses at IRRI in the early 1960s - upcagolden2010.wordpress.com - Mr. Herrera arrived at IRRI in 1961 as a research aide and retired 36 years later in 1997 as a senior assistant scientist. Below is his poem-essay about how, in rice breeding, marriage respects no boundaries. Marriage Respects No Boundaries by Rizal M. Herrera IRRI rice breeder, 1961-97 Innocent-looking rice plants also engage in courtship and marriage practices. The rites are simple, devoid of elegant, expensive entourage, and there are no high government officials in flashy cars acting as principal sponsors. The bride, the superstar of the occasion, is not in the usual wedding gown attraction. She is not clad in almost see-through Pitoy #39;s creation from veil to trailings. She is simply a dark green rice plant with flowers stripped off its anthers, the male counterpart of the species. When ...From:irrivideoViews:12 1ratingsTime:10:26More inEducation

Continued here:
Ceremony for the 100000th rice-breeding cross, a major milestone in IRRI's 52-year history - Video

Recommendation and review posted by Bethany Smith

Gene Knockout - Wiki Article
A gene knockout (abbreviation: KO) is a genetic technique in which one of an organism #39;s genes is made inoperative ("knocked out" of the organism). Also known as knockout organisms or simply knockouts... Gene Knockout - Wiki Article - wikiplays.org Original @ http All Information Derived from Wikipedia using Creative Commons License: en.wikipedia.org Author: Maggie Bartlett, NHGRI. Image URL: en.wikipedia.org ( This work is in the Public Domain. ) Author: Maggie Bartlett, NHGRI. Image URL: en.wikipedia.org ( This work is in the Public Domain. ) Author: en.wikipedia.org Image URL: en.wikipedia.org ( Copyright holder allows use with attribution. ) Author: Lexicon Genetics Incorporated Image URL: en.wikipedia.org ( This work is in the Public Domain. )From:WikiPlaysViews:0 0ratingsTime:05:23More inEducation

Go here to read the rest:
Gene Knockout - Wiki Article - Video

Recommendation and review posted by Bethany Smith

Crops and Climate Proofing - Trude Schwarzacher and Pat Heslop Harrison for IAEA
Superdomestication and feed-forward plant breeding: Genomic and molecular cytogenetic approaches Pat Heslop-Harrison and Trude Schwarzacher, University of Leicester, UK phh4(a)le.ac.uk and ts32(a)le.ac.uk http://www.molcyt.com Today I am presenting some of our work contributing and relating to the IAEA/FAO Coordinated Research Programme on Climate Proofing of Food Crops: Genetic Improvement for Adaptation to High Temperatures in Drought Prone Areas and Beyond (www.webcitation.org ) We all know why we are here and having these important discussions, and climate change and its mitigation are critical: this was the top story on the IAEA homepage last month, reporting on a talk by Modibo Traore: he noted how we have the combination of climate change damaging soil and threatening agriculture as we practice it now, along with unprecedented numbers of people to feed. Some of the challenges are summed up in this photograph from south of Addis Abbaba in the the Rift Valley of Ethiopia. Drought and unpredictable climate prevent crops timely establishment of crops, and the consequences are exacerbated by overgrazing and collection of trees for fuelwood, themselves consequences of population growth, and all leading to loss of soil - seen in the dust storm on the left. In the background though, you can see the product of one of the huge natural resources of Ethiopia: carbon-free electricity from hydroelectric and geothermal sources, rather than nuclear, and certainly part of the solution to ...From:Pat Heslop-HarrisonViews:3 0ratingsTime:18:20More inEducation

Read more here:
Crops and Climate Proofing - Trude Schwarzacher and Pat Heslop Harrison for IAEA - Video

Recommendation and review posted by Bethany Smith

BOTHELL, Wash.--(BUSINESS WIRE)--

Seattle Genetics, Inc. (SGEN) announced today that ADCETRIS (brentuximab vedotin) has been granted orphan drug designation by the U.S. Food and Drug Administration (FDA) for the treatment of mycosis fungoides (MF). MF is the most common type of cutaneous T-cell lymphoma (CTCL). Seattle Genetics and its ADCETRIS collaborator, Millennium: The Takeda Oncology Company, are conducting the ALCANZA trial, a phase III clinical trial of ADCETRIS for patients with CD30-positive relapsed CTCL, including MF. ADCETRIS is not approved for the treatment of CTCL.

This orphan drug designation is a part of our ADCETRIS regulatory strategy, designed to complement the Special Protocol Assessment for the ongoing ALCANZA study, said Clay B. Siegall, President and Chief Executive Officer of Seattle Genetics. The encouraging data from investigator-sponsored trials of ADCETRIS in CTCL, which will be presented at ASH, provide further support for our activities in this patient population.

FDA orphan drug designation is intended to encourage companies to develop therapies for the treatment of diseases that affect fewer than 200,000 individuals in the United States. This designation provides Seattle Genetics with the opportunity for seven years of marketing exclusivity, grant funding to defray costs of clinical trial expenses, tax credits for clinical research expenses and potential waiver of the FDA's application user fee.

The ALCANZA trial is a randomized phase III clinical trial of ADCETRIS for relapsed CD30-positive CTCL patients. The trial is assessing ADCETRIS versus investigators choice of methotrexate or bexarotene in patients with CD30-positive CTCL, including those with primary cutaneous anaplastic large cell lymphoma (pcALCL) or MF. The primary endpoint of the study is overall response rate lasting at least 4 months. Approximately 124 patients will be enrolled in the pivotal trial. The ALCANZA trial is being conducted under a Special Protocol Assessment agreement from the FDA. The study also received European Medicines Agency scientific advice. For more information about the ALCANZA trial, visit http://www.clinicaltrials.gov.

At the 54th American Society of Hematology (ASH) Annual Meeting and Exposition being held December 8-11, 2012 in Atlanta, GA, data from two investigator-sponsored trials of ADCETRIS in CTCL will be reported:

Brentuximab vedotin demonstrates significant clinical activity in relapsed or refractory mycosis fungoides with variable CD30 expression (Abstract #797)

Results of a phase II trial of brentuximab vedotin (SGN-35) for CD30-positive cutaneous T-cell lymphomas and lymphoproliferative disorders (Abstract #3688)

About ADCETRIS

ADCETRIS (brentuximab vedotin) is an ADC comprising an anti-CD30 monoclonal antibody attached by a protease-cleavable linker to a microtubule disrupting agent, monomethyl auristatin E (MMAE), utilizing Seattle Genetics proprietary technology. The ADC employs a linker system that is designed to be stable in the bloodstream but to release MMAE upon internalization into CD30-expressing tumor cells.

Continued here:
Seattle Genetics Receives FDA Orphan Drug Designation for ADCETRIS® (Brentuximab Vedotin) in Mycosis Fungoides

Recommendation and review posted by Bethany Smith

SALT LAKE CITY, Nov. 28, 2012 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (MYGN) announced today that a presentation entitled "CCP Score Significantly Predicts PSA Failure After EBRT," was presented on Wednesday, November 28th, 2012 at the Annual Meeting of the Society of Urological Oncology in Bethesda, Maryland. The study demonstrates that the Prolaris(R) test, which measures cell cycle progression (CCP) genes, significantly predicts PSA biochemical recurrence in patients after treatment with external beam radiation therapy (EBRT).

Researchers at Durham VA Medical Center, Duke University School of Medicine, and Myriad Genetics analyzed biopsy specimens from 152 patients with prostate cancer. In this prospectively collected cohort, the Prolaris test was a significant predictor of biochemical recurrence in patients that had undergone radiation treatment (p=0.0017). After adjustment for Gleason score, PSA percent positive cores, and concurrent anti-hormone therapy, the Prolaris test accurately predicted those patients who would benefit from radiation therapy (p=0.034).

"Current approaches to the management of patients with prostate cancer lead to significant under and overtreatment of patients," said Dr. Stephen Freedland, Durham VA Medical Center and Duke University School of Medicine. "Measurement of the CCP score identifies prostate cancer patients at high risk of progression despite conventional radiation therapy who might be considered for more aggressive treatment regimens."

Approximately 25% of men who undergo primary radiation therapy will suffer potentially life threatening disease recurrence and progression. The Prolaris test could be used to identify these at-risk patients prior to their initial treatment. These patients may be appropriate candidates for more aggressive combination therapies such as radiation with anti-androgen therapy or chemotherapy.

The clinically important information that Prolaris provides cannot be obtained from currently available clinical parameters. In addition, this is the first Prolaris study that contained a significant number of African American men, a population known to be at especially high risk for aggressive prostate cancer.

About Prolaris

Prolaris is a genomic risk stratification test developed to aid physicians in predicting prostate cancer aggressiveness in conjunction with clinical parameters such as Gleason score and PSA. Prolaris is a direct molecular measure of prostate cancer tumor biology. By measuring the expression levels of genes involved with cancer replication, Prolaris is able to more accurately predict disease progression and enable physicians to better define a treatment/monitoring strategy for their patients. Prolaris is significantly more prognostic than currently used clinicopathologic variables and provides unique additional information that can be combined with other clinical factors to make the most accurate prediction of a patient's cancer aggressiveness and therefore disease progression.

Prolaris has been proven to predict clinical progression in 4 different clinical cohorts, in both pre and post-treatment scenarios.

About Myriad Genetics

Myriad Genetics is a leading molecular diagnostic company dedicated to making a difference in patients' lives through the discovery and commercialization of transformative tests to assess a person's risk of developing disease, guide treatment decisions and assess risk of disease progression and recurrence. Myriad's portfolio of molecular diagnostic tests are based on an understanding of the role genes play in human disease and were developed with a commitment to improving an individual's decision making process for monitoring and treating disease. Myriad is focused on strategic directives to introduce new products, including companion diagnostics, as well as expanding internationally. For more information on how Myriad is making a difference, please visit the Company's website: http://www.myriad.com.

The rest is here:
Myriad Genetics' Prolaris Test Predicts Biochemical Recurrence in Prostate Cancer Patients Following Radiation Therapy

Recommendation and review posted by Bethany Smith

SCMOM 2012_Sistemic
Sistemic #39;s world leading expertise is on applying microRNA profiling in context with the biology, to areas where there is currently an unmet need for sophisticated tools delivering instructive and robust knowledge of the cell system. From their SistemQC trade; platform they have derived an extensive suite of tools for the cell therapy, gene therapy and bioprocessing community. SistemQC trade;, molecularly characterises cells including stem cells as well as aids in the optimization and monitoring (QC) of the manufacture process. More specifically the initial focus of SistemQC trade; by clients has been on generation of microRNA based ID markers, purity potency assessment and manufacture monitoring optimization. http://www.sistemic.co.uk Presenter: Jim Reid, Chairman and CEO, SistemicFrom:AllianceRegenMedViews:3 1ratingsTime:11:56More inScience Technology

Original post:
SCMOM 2012_Sistemic - Video

Recommendation and review posted by Bethany Smith

Gene Therapy against
From:HDTalkHealthDebateViews:0 0ratingsTime:05:23More inScience Technology

Continued here:
Gene Therapy against - Video

Recommendation and review posted by Bethany Smith

Episode 1. Uncovering Genetic Code
#12298;Unveiling the Secrets of Biotechnology #65306;Volume #8741; #12299; Part 1 #65306;Secrets Left by Our Ancestors Part 2 #65306;The Antidote to Rare Diseases -- Gene Therapy Part 3 #65306;Opening DNA #39;s Pandora #39;s BoxFrom:ccleestagViews:0 0ratingsTime:23:34More inScience Technology

Read more:
Episode 1. Uncovering Genetic Code - Video

Recommendation and review posted by Bethany Smith

Gene Therapy - Wiki Article
Gene therapy is the use of DNA as a pharmaceutical agent to treat disease. It derives its name from the idea that DNA can be used to supplement or alter genes within an individual #39;s cells as a therap... Gene Therapy - Wiki Article - wikiplays.org Original @ http All Information Derived from Wikipedia using Creative Commons License: en.wikipedia.org Author: Unknown Image URL: en.wikipedia.org ( This work is in the Public Domain. )From:WikiPlaysViews:0 0ratingsTime:33:40More inEducation

See original here:
Gene Therapy - Wiki Article - Video

Recommendation and review posted by Bethany Smith

SCMOM 2012_NeoStem
NeoStem, Inc. is an emerging technology leader in the fast-developing cell therapy market. Its business strategy combines a state-of-the-art contract development and manufacturing subsidiary, Progenitor Cell Therapy, LLC, with a medically important cell therapy product development program. NeoStem #39;s most clinically advanced therapeutic, AMR-001, is being developed at its Amorcyte subsidiary, which is enrolling patients in a Phase 2 trial for preservation of heart function after a heart attack. Athelos Corporation, also a NeoStem subsidiary, is in early stage clinical exploration of a T-cell therapy for autoimmune conditions. Pre-clinical assets include our VSELTM Technology platform and our mesenchymal stem cell product candidate for regenerative medicine. http://www.neostem.com Presenter: Jonathan Sackner-Bernstein, NeoStem, Inc.From:AllianceRegenMedViews:4 1ratingsTime:14:54More inScience Technology

Read more from the original source:
SCMOM 2012_NeoStem - Video

Recommendation and review posted by simmons

SCMOM 2012_Regen BioPharma, Inc.
The Regen BioPharma business model is to take multiple stem cell therapeutics to and through the human "safety and signal of efficacy" stage (Phase I/II clinical trials). The approach is a highly focused analysis of issued patents in regenerative medicine, identification and acquisition of undervalued assets that have demonstrated proof of concept, and forming companies around these assets. Having assembled a core infrastructure specialized in obtaining regulatory approval and executing clinical trials in cell therapy, we aim to act as a "superincubator" that within 18 - 24 months grows technologies from laboratory to an asset ready for spin-off or sale to feed the pipeline of Big Pharma. http://www.regenbiopharma.com Presenter: J. Christopher Mizer, President, Regen BioPharma, Inc.From:AllianceRegenMedViews:4 1ratingsTime:09:13More inScience Technology

Read more:
SCMOM 2012_Regen BioPharma, Inc. - Video

Recommendation and review posted by simmons

Washington, November 28 (ANI): When mesenchymal cells derived from skeletal muscle (SM-MSCs) or adipose tissue (ADSCs) were injected into the heart muscle (myocardium) of separate groups of laboratory rats that had suffered a myocardial infarction, rats in both groups experienced significantly improved left ventricle function and smaller infarct size after cell therapy, a study has found.

The study, carried out by researchers at Oslo University Hospital and the Norwegian Center for Stem cell Research, Oslo University, sought to determine if MSCs from different organs would result in different functional outcomes.

"Despite advances in revascularization and medical therapy, acute myocardial infarction (AMI) and heart failure are still important causes of morbidity and mortality in industrialized countries," said study co-author Dr. Jan E. Brinchmann of the Norwegian center for Stem Cell Research at Oslo University Hospital, Oslo.

"AMI leads to a permanent loss of contractile elements in the heart and the formation of fibrous scarring. Regeneration of contractile myocardium has been a target of cell therapy for more than a decade," he added.

According to Dr. Brinchmann, MSCs tolerate hypoxia, secrete angiogenic factors and have been shown to improve vascularization; thus, they have properties suggesting that they may beneficially impact AMI, chronic heart failure and angina pectoris after cell transplantation.

Following injection into the "border zone" and infarct area of immunodeficient rats one week after induced myocardial infarction, the researchers used echocardiography to measure myocardial function and other analyses to measure the size of scaring, density of blood vessels in the scar, and the health of myocardial tissues.

"Our results showed that intramyocardial injection of both ADSCs and SM-MSCs one week after AMI led to a substantial decrease in infarct size and a significant improvement in left ventricle function when compared with injections of cell culture medium alone," concluded the researchers.

"There was a trend toward better functional improvement in the SM-MSC group when compared to the ADSC group, but this did not reach significance," they added.

They concluded that many questions remain unanswered, including the question of whether MSCs isolated from different organisms could result in different functional outcomes.

Other unanswered questions relate to the optimal time delay between the onset of myocardial infarction and injection of MSCs. These cells do, however, still appear to be "a potentially interesting adjuvant treatment modality for selected patients following acute myocardial infarction," they concluded.

See the original post:
Different organ-derived stem cell injections improve heart function in rats

Recommendation and review posted by simmons

Public release date: 27-Nov-2012 [ | E-mail | Share ]

Contact: Robert Miranda cogcomm@aol.com Cell Transplantation Center of Excellence for Aging and Brain Repair

Putnam Valley, NY. (Nov. 27, 2012) A study published in the current issue of Cell Transplantation (21:8), now freely available on-line at http://www.ingentaconnect.com/content/cog/ct/, has found that when mesenchymal cells derived from skeletal muscle (SM-MSCs) or adipose tissue (ADSCs) were injected into the heart muscle (myocardium) of separate groups of laboratory rats that had suffered a myocardial infarction, rats in both groups experienced significantly improved left ventricle function and smaller infarct size after cell therapy.

The study, carried out by researchers at Oslo University Hospital and the Norwegian Center for Stem cell Research, Oslo University, sought to determine if MSCs from different organs would result in different functional outcomes.

"Despite advances in revascularization and medical therapy, acute myocardial infarction (AMI) and heart failure are still important causes of morbidity and mortality in industrialized countries," said study co-author Dr. Jan E. Brinchmann of the Norwegian center for Stem Cell Research at Oslo University Hospital, Oslo. "AMI leads to a permanent loss of contractile elements in the heart and the formation of fibrous scarring. Regeneration of contractile myocardium has been a target of cell therapy for more than a decade."

According to Dr. Brinchmann, MSCs tolerate hypoxia, secrete angiogenic factors and have been shown to improve vascularization; thus, they have properties suggesting that they may beneficially impact AMI, chronic heart failure and angina pectoris after cell transplantation. Following injection into the "border zone" and infarct area of immunodeficient rats one week after induced myocardial infarction, the researchers used echocardiography to measure myocardial function and other analyses to measure the size of scaring, density of blood vessels in the scar, and the health of myocardial tissues.

"Our results showed that intramyocardial injection of both ADSCs and SM-MSCs one week after AMI led to a substantial decrease in infarct size and a significant improvement in left ventricle function when compared with injections of cell culture medium alone," concluded the authors. "There was a trend toward better functional improvement in the SM-MSC group when compared to the ADSC group, but this did not reach significance."

They concluded that many questions remain unanswered, including the question of whether MSCs isolated from different organisms could result in different functional outcomes. Other unanswered questions relate to the optimal time delay between the onset of myocardial infarction and injection of MSCs. These cells do, however, still appear to be "a potentially interesting adjuvant treatment modality for selected patients following acute myocardial infarction," they concluded.

###

Contact: Dr. Jan E. Brinchmann, Norwegian Center for Stem Cell Research, Institute of Basic Medical Sciences, Oslo University Hospital Rikshospitalet and University of Oslo, PO Box 1121 Blindern 0317 Oslo, Norway. Tel. +42-22-84-04-89 Fax. +42-22- 85-10-58 Email: jan.brinchmann@rr.research.no

See original here:
Study suggests different organ-derived stem cell injections improve heart function

Recommendation and review posted by simmons

PHILADELPHIA, Nov. 26, 2012 /PRNewswire/ --RRY Publications LLC today announced that the use of stem cell therapies in 2012 significantly exceeded forecasts which were originally presented at the February 2012 New York Stem Cell Summit. Said Robin Young, stem cell industry analyst and host of the New York meeting: "The range and scope of stem cell therapeutic use in the United States grew much faster than we'd forecasted earlier this year. Virtually all of the increases we're seeing are for adult stem cell therapies and, in particular, the use by physicians of both allograft and autologous stem cell products. It would not be an exaggeration to call this unexpected and remarkable growth."

Mr. Young's revised forecast of stem cell commercialization revenues for 2013-2020 will be presented at the February meeting in New York.

The companies, scientists and physicians that are at the forefront of this remarkable increase in stem cell therapeutic use will be presenting at the 8th Annual New York Stem Cell Summit. Listed below is the preliminary lineup of presenters for the 8th Annual Stem Cell Summit.

The Stem Cell Summit, an intensive one-day event, allows attendees to learn about the latest developments in the stem cell marketplace, evaluate the groundbreaking stem cell products physicians are using today, and discover the growing market potential in terms of revenues. For 2013, the Summit will feature 30+ presenters, a research review and debate session, and a special track on expanding the range of stem cell therapies.

The 8th Annual Stem Cell Summit will take place on Feb. 19, 2013, at Bridgewaters in the heart of New York City's historic South Street Seaport. The preliminary roster of companies featured will include representatives from 2012 presenters and new 2013 presenters.

Aastrom Biosciences, Inc.

Advanced Cell Technology

Aldagen, Inc.

AllCells, LLC.

Aruna Biomedical, Inc.

Original post:
Dramatic Rise in Stem Cell Therapy Use in 2012

Recommendation and review posted by simmons

First Annual Research Day
On November 15, 2012, the Biomedical Research Institute (BRI) at Brigham and Women #39;s Hospital held its first Research Day. The event featured 150 poster presentations by leading BWH researchers on today #39;s hottest health topics such as obesity, healthy aging and personalized medicine. Dr. Robert C. Green was named the winner of the $100000 BRIght Futures Prize, after a unique competition in which nearly 6500 online votes from people across the globe determined the winning project. Dr. Green #39;s project explores the use of genome sequencing in newborns. The other BRIght Futures finalists included a project jointly led by Drs. Phil DeJager and Elizabeth Karlson, whose proposal focused on using genetics and electronic health records to treat multiple sclerosis and a project led by Dr. Robert Plenge, whose proposal focused on the use of technology to unravel the mysteries of the immune system.From:BrighamandwomensViews:3 0ratingsTime:03:47More inNonprofits Activism

See more here:
First Annual Research Day - Video

Recommendation and review posted by sam

The Back Up Singers "Something Inside So Strong"
Make a donation today to see the video in full: uk.virginmoneygiving.com A group of British legal professionals have swapped the courtroom for the recording studio in a bid to raise vital funds for Back Up. #39;The Back Up Singers #39;, as they are known, met in 2011 at a networking event and decided to form a choir to show the lighter side of their profession and to highlight the distressing psychological effects of spinal cord injury.From:BackUpTrustViews:111 2ratingsTime:01:16More inNonprofits Activism

Continue reading here:
The Back Up Singers "Something Inside So Strong" - Video

Recommendation and review posted by sam

Holiday Message from Mary Fran Menge
"I would not be walking today had it not been for Mary Free Bed," says patient Mary Fran Menge of L #39;Anse, MI. In 2009, Mary was in an automobile accident that left her with a severe spinal cord injury. With the help of robotic-assisted therapy and a lot of determination, Mary is now able to walk.From:MaryFreeBedViews:141 0ratingsTime:00:45More inEducation

Read more here:
Holiday Message from Mary Fran Menge - Video

Recommendation and review posted by sam

Public Forum on Clinical Trials in Spinal Cord Injury 2012
The Public Forum on Clinical Trials in Spinal Cord Injury offered an opportunity to learn about spinal cord research advances in "lay" language from leading international spinal cord scientists.From:WesternUniversityViews:9 0ratingsTime:01:01:24More inEducation

Continued here:
Public Forum on Clinical Trials in Spinal Cord Injury 2012 - Video

Recommendation and review posted by sam

Dr. Sasha Rabchevsky - J. Allyn Taylor International Prize in Medicine Symposium 2012
Sasha Rabchevsky, PhD, Associate Professor of Physiology, Spinal Cord Brain Injury Research Center (SCoBIRC), University of Kentucky, Lexington, KY. Modulation of intraspinal plasticity associated with autonomic dysreflexia after complete spinal cord injury.From:WesternUniversityViews:9 0ratingsTime:48:17More inEducation

Follow this link:
Dr. Sasha Rabchevsky - J. Allyn Taylor International Prize in Medicine Symposium 2012 - Video

Recommendation and review posted by sam

RIP Scripps Ranch Motorcross Racer - Jantz Grodzicki Dies After Crash
RIP Bravery Jantz GrodzickI - MX For Life This is Chris, Jantz #39;s dad... I wanted to first thank everyone for the heartfelt prayers for Jantz. I need to ask everyone the favor of including Jantz in your prayers as we move through this painful journey. Jantz sustained a devastating brain cell and spinal cord injury. He was wearing a layete brace and shoei helmet. We left the hospital last night with zero hope from the doctors of his survival chances. His heart stopped at the track and he was pronounced brain dead at the hospital with no response. He was however put on life support until we decided on the options available that I hope none if you ever half to face. A short while ago we received a call from the doctor that a miracle took place this morning at 6:30am that Jantz #39;s "condition has changed significantly" he is responding to eye commands, left to right, up and down and raise your eyebrows. Still no other responses other than this. Given what we were told this is truly a miracle. The thoughts and prayers shared here and on Facebook are what have helped him to make a move off the line. The race for recovery is just beginning and we can only pray that God will pull him through. May god bless each of you and your families. The Grodzicki Family.... Scripps Ranch motocross racer, Jantz Grodzicki, dies after crash. Friends and family are mourning the loss of a local teen motocross racer who died after a racing crash in Florida.From:xBadBoyZz ClanViews:1424 10ratingsTime:01:03More inAutos Vehicles

Read more:
RIP Scripps Ranch Motorcross Racer - Jantz Grodzicki Dies After Crash - Video

Recommendation and review posted by sam

How I Recovered Bladder Function After A Spinal Cord Injury
Molly Hale speaks of the ideas she used to recover her bladder function after a spinal cord injury.From:abilityproductionViews:0 1ratingsTime:14:14More inEducation

Follow this link:
How I Recovered Bladder Function After A Spinal Cord Injury - Video

Recommendation and review posted by sam

Ekso Bionics #39; Lyne Vale: Full talk and live exoskeleton demo at Wired 2012
Full story: http://www.wired.co.uk Lynn Vale is a physiotherapist specialising in neurology, spinal cord injuries and rehabilitation. Working at Ekso Bionics, Vale helps spinal cord injury patients and people with other neurological disorders to walk again with the help of their exoskeleton, the Ekso. Formed in 2005 as Berkeley ExoWorks, the group began revolutionising the field of bionic exoskeletons to augment human mobility and capability. It #39;s first models of exoskeleton legs allowed users to carry huge loads up slopes and stairs, aiding hikers and soldiers in lifting work. In 2011 the group became Ekso Bionics, producing exoskeletons to help people with serious injuries and neurological disorders to walk. Ekso Bionics have worked with well over three hundred patients and dozens of clinicians and researchers to understand how to apply these technical breakthroughs to the advancement of human motion. Ekso was demonstrated live at Wired 2012.From:WiredVideoUKViews:398 2ratingsTime:16:17More inScience Technology

See more here:
Ekso Bionics' Lyne Vale: Full talk and live exoskeleton demo at Wired 2012 - Video

Recommendation and review posted by sam